Characterization of hyperbranched core-multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa

Item Type:	Article
Title:	Characterization of hyperbranched core-multishell nanocarriers as an innovative drug delivery system for the application at the oral mucosa
Creators Name:	Jager, J. and Obst, K. and Lohan, S.B. and Viktorov, J. and Staufenbiel, S. and Renz, H. and Unbehauen, M. and Haag, R. and Hedtrich, S. and Teutloff, C. and Meinke, M..C. and Danker, K. and Dommisch, H.
Abstract:	BACKGROUND AND OBJECTIVES: In the oral cavity, the mucosal tissues may develop a number of different pathological conditions, such as inflammatory diseases (gingivitis, periodontitis) and autoimmune disorders (eg, oral lichen planus) that require therapy. The application of topical drugs is one common therapeutic approach. However, their efficacy is limited. Dilution effects due to saliva hinder the adherence and the penetration of drug formulations. Therefore, the bioavailability of oral topical drugs is insufficient, and patients may suffer from disease over years, if not life-long. MATERIAL AND METHODS: In the present study, we characterized core-multishell (CMS) nanocarriers for their potential use as drug delivery systems at oral mucosal tissues. For this purpose, we prepared porcine masticatory as well as buccal mucosa and performed Franz cell diffusion experiments. Penetration of fluorescently labeled CMS nanocarriers into the mucosal tissue was analyzed using confocal laser scanning microscopy. Upon exposure to CMS nanocarriers, the metabolic and proliferative activity of gingival epithelial cells was determined by MTT and sulforhodamine B assays, respectively. RESULTS: Here, we could show that the carriers penetrate into both mucosal tissues, while particles penetrate deeper into the masticatory mucosa. Electron paramagnetic resonance spectroscopy revealed that the 3-carboxy-2,2,5,5-tetramethyl-1-pyrrolidinyloxy-labeled glucocorticoid dexamethasone loaded on to the CMS nanocarriers was released from the carriers in both mucosal tissues but with a higher efficiency in the buccal mucosa. The release from the nanocarriers is in both cases superior compared to the release from a conventional cream, which is normally used for the treatment of inflammatory conditions in the oral cavity. The CMS nanocarriers exhibited neither cytotoxic nor proliferative effects in vitro. CONCLUSION: These findings suggested that CMS nanocarriers might be an innovative approach for topical drug delivery in the treatment of oral inflammatory diseases.
Keywords:	CMS Nanocarrier, Drug Delivery System, Epithelial Cells, Oral Mucosa, Animals
Source:	Journal of periodontal research
ISSN:	1600-0765
Publisher:	Wiley
Volume:	53
Number:	1
Page Range:	57-65
Date:	February 2018
Official Publication:	https://doi.org/10.1111/jre.12487
PubMed:	View item in PubMed

Repository Staff Only: item control page